Intra-patient heterogeneity of BRAF mutation status: fact or fiction?

by Menzies, A M, Wilmott, J S, Long, G V, Scolyer, R A
Published 2014

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma

by Hu, W, Jin, L, Jiang, C C, Long, G V, Scolyer, R A, Wu, Q, Zhang, X D, Mei, Y, Wu, M
Published 2013

BRAFV600E protein expression and outcome from BRAF inhibitor treatment in BRAFV600E metastatic melanoma

by Wilmott, J S, Menzies, A M, Haydu, L E, Capper, D, Preusser, M, Zhang, Y E, Thompson, J F, Kefford, R F, von Deimling, A, Scolyer, R A, Long, G V
Published 2013

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

by Long, G. V., Atkinson, V., Ascierto, P. A., Robert, C., Hassel, J. C., Rutkowski, P., Savage, K. J., Taylor, F., Coon, C., Gilloteau, I., Dastani, H. B., Waxman, I. M., Abernethy, A. P.
Published 2016

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

by Bowyer, S, Prithviraj, P, Lorigan, P, Larkin, J, McArthur, G, Atkinson, V, Millward, M, Khou, M, Diem, S, Ramanujam, S, Kong, B, Liniker, E, Guminski, A, Parente, P, Andrews, M C, Parakh, S, Cebon, J, Long, G V, Carlino, M S, Klein, O
Published 2016

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma

by Carlino, M S, Haydu, L E, Kakavand, H, Menzies, A M, Hamilton, A L, Yu, B, Ng, C C, Cooper, W A, Thompson, J F, Kefford, R F, O'Toole, S A, Scolyer, R A, Long, G V
Published 2014